Loading...Loading...In addition to the summary of monthly changes below, please also review our monthly Bulletin for recent and upcoming changes to our medical and reimbursement policies, Clinical Position Statements and associated changes to pre-authorization requirements. The Medical Policy Manual includes a list of recent updates and archived policies. Monthly change summaries are added to our website within 10 business days of our newsletter publication.
Review other monthly changes for 2022.
The following codes were added to our pre-authorization lists effective August 1, 2022:
Commercial
- Cytochrome p450 and VKORC1 Genotyping for Treatment Selection and Dosing (#GT10)
- 81227
- Evaluating the Utility of Genetic Panels (#GT64)
- 81227
Genetic and Molecular Diagnostic Testing (#GT20)
- 81227
Medicare Advantage
Hypoglossal Nerve Stimulation (#M-SUR215)
- C1767
Please review our pre-authorization lists for all updates and pre-authorize services accordingly. You can submit standard medical pre-authorizations through Availity Essentials. Learn more about electric authorizations.
The following updates were made to our Administrative Manual on August 1, 2022:
- BlueCard Program
- Facility Guidelines
Hospice VBID Model (Regence BCBSO and Regence BCBSU only)
We publish updates to medical and reimbursement policies in our monthly publication, The Bulletin. Subscribe to receive an email notification when issues are published.
Medical policy updates
We provided 90-day notice in the May 2022 issue of The Bulletin about the following medical policies, which are effective August 1, 2022:
- Implantable Peripheral Nerve Stimulation and Peripheral Subcutaneous Field Stimulation (#SUR205)
- Noninvasive Prenatal Testing to Determine Fetal Aneuploidies, Microdeletions, and Twin Zygosity Using Cell-Free DNA (#GT44)
Occipital Nerve Stimulation (#SUR174)
Reimbursement policy updates
We provided 90-day notice in the May 2022 issue of The Bulletin about the following reimbursement policies, which are effective August 1, 2022:
- Correct Coding Guidelines (Administrative #129)
- DME Purchase and Rental Limitations and Reimbursement (commercial and Medicare Advantage Administrative #131)
Reimbursement of Intravenous (IV) Solutions, Premixed IV Medications, Epidural, Intra-arterial and Intrathecal Solutions and Total Parenteral Nutrition (TPN) for Facilities (Facility #109)
We publish updates to medical policies in our monthly publication, The Bulletin. Subscribe to receive an email notification when issues are published.
We provided 90 day notice in the May 2022 issue of The Bulletin about the following medical policies, which are effective August 1, 2022:
- Implantable Peripheral Nerve Stimulation and Peripheral Subcutaneous Field Stimulation (#SUR205)
- Noninvasive Prenatal Testing to Determine Fetal Aneuploidies, Microdeletions, and Twin Zygosity Using Cell-Free DNA (#GT44)
Occipital Nerve Stimulation (#SUR174)
We publish updates to reimbursement policies in our monthly publication, The Bulletin. Subscribe to receive an email notification when issues are published.
We provided 90-day notice in the May 2022 issue of The Bulletin about the following reimbursement policies, which are effective August 1, 2022:
- Correct Coding Guidelines (Administrative #129)
- DME Purchase and Rental Limitations and Reimbursement (commercial and Medicare Advantage Administrative #131)
- Reimbursement of Intravenous (IV) Solutions, Premixed IV Medications, Epidural, Intra-arterial and Intrathecal Solutions and Total Parenteral Nutrition (TPN) for Facilities (Facility #109)